Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
08/2000
08/10/2000CA2398197A1 Delivery system and methods for gene therapy
08/10/2000CA2362126A1 B7rp-1 polypeptides
08/10/2000CA2361838A1 Method of treating cancer by restoration of pp32 function
08/10/2000CA2361615A1 The use of vascular endothelial growth factor 2 antagonist in the treatment of an injury to or disorder of an eye
08/10/2000CA2361555A1 Hydrogel particle formulations
08/10/2000CA2361551A1 Method for controlling liposome size
08/10/2000CA2361459A1 Use of cationic lipids to generate anti-tumor immunity
08/10/2000CA2361191A1 Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
08/10/2000CA2360942A1 Preparations for preventing and/or treating a tissue change of mesenchymal origin
08/10/2000CA2360878A1 Gene repair involving excision of targeting dna
08/10/2000CA2360858A1 Genetically engineered retroviral vector particles capable of infecting non-dividing cells
08/10/2000CA2360796A1 Improved helper dependent vector system for gene therapy
08/10/2000CA2360640A1 Genetic and epigenetic regulation of abc transporters and ect0-phosphatases for the modulation of drug resistance
08/10/2000CA2359469A1 Compositions and methods for treating and preventing pathogenic bacterial infection based on the essential role of dna methylation in bacterial virulence
08/09/2000EP1026253A2 Expression of exogenous polynucleotide sequences in a vertebrate
08/09/2000EP1026251A2 Transgenic animals expressing human P25
08/09/2000EP1026250A1 DNA-constructs of blood clotting factors and P-selectin
08/09/2000EP1025871A1 Use of a melanoma inhibiting activity factor (MIA) for cartilage and bone repair
08/09/2000EP1025849A1 Methods for detection and treatment of individuals having abnormal cells expressing HLA-A2/tyrosinase peptide antigens
08/09/2000EP1025244A2 NOVEL MODIFIED MSP-1 NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING mRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS
08/09/2000EP1025242A1 A method of inhibiting an immune response to a recombinant vector
08/09/2000EP1025237A2 Human checkpoint kinase, hcds1, compositions and methods
08/09/2000EP1025236A2 Human checkpoint kinase, hcds1, compositions and methods
08/09/2000EP1025233A2 Novel modified nucleic acid sequences and methods for increasing mrna levels and protein expression in cell systems
08/09/2000EP1025223A2 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
08/09/2000EP1025222A1 Genetic and protein therapy products for treating cystic fibrosis and inducing a glutathione-s-transferase function
08/09/2000EP1025216A1 Transgenic animal models for cardiac hypertrophy and uses thereof
08/09/2000EP1025212A2 Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
08/09/2000EP1025208A2 A packaging cell line producing siv-pseudotyped mlv
08/09/2000EP1025122A1 Fibroblast growth factor with hepatocyte proliferation activity
08/09/2000EP1025121A1 PEPTIDES CAPABLE OF INHIBITING THE INTERACTION BETWEEN PRESENILINS AND THE $g(b)-AMYLOID PEPTIDE OR ITS PRECURSOR
08/09/2000EP1024836A1 Method of delivering genes to antigen presenting cells of the skin
08/09/2000EP1024828A1 NOVEL pheS (BETA)
08/09/2000EP1024825A1 Xenogeneic cholesteryl ester transfer protein (cetp) for modulation of cetp activity
08/09/2000EP1024823A1 Prevention and treatment of adhesion formation
08/09/2000EP1024821A1 Novel prokaryotic polynucleotides, polypeptides and their uses
08/09/2000EP1024820A1 Androgen activity antagonists as therapies for anorexia, anorexia nervosa, and disorders characterized by a pathologically underweight condition
08/09/2000EP0533846B1 The ciliary neurotrophic factor receptor
08/08/2000US6100444 Nucleotide sequences coding prostate gland protein; for the treatment of prostate cancer
08/08/2000US6100443 Universal donor cells
08/08/2000US6100244 Method for treating respiratory distress by sublingual administration of DNA
08/08/2000US6100243 Method of sensitizing tumor cells with adenovirus E1A
08/08/2000US6100242 Gene therapies for enhancing cardiac function
08/08/2000US6100235 Methods of treating immune and inflammatory response with IL-17 receptors
08/08/2000US6100090 Compound 8 to 30 nucleobases in length targeted coding region of human phosphatidyl inositol 3'-kinase p85; therapy and diagnosis of diseases related hormone and growth factor receptors and oncogene products
08/08/2000US6100088 Viral vaccines
08/08/2000US6100087 Ribozymes targeted to human CCR5 mRNA
08/08/2000US6100086 Expression construct of transgene, regulatory sequences, and adenoviral sequences; facilitates persistent expression of transgene in cells and protects cells from cell-mediated immune responses; gene therapy especially for cystic fibrosis
08/08/2000US6100060 Recombinant expression system of polynucleotide encoding a specific amino acid sequence and present in a host cell; for recombinant production of wnt-5b polypeptides important in developmental signal transduction
08/08/2000US6100059 Compounds
08/08/2000US6099841 Include hgf receptor antibodies and fragments thereof; used to treat a pathological liver condition
08/08/2000US6099832 Transplants for myocardial scars
08/08/2000US6099831 Recombinant vectors of viral origin which contain a nucleotide sequence coding for a specific polypeptide, and their use for the expression of this polypeptide in muscle cells; used as medicines in the field of muscle diseases
08/08/2000US6099823 Compositions and methods for the treatment and diagnosis of cardiovascular disease
08/08/2000CA2233144C Arf-p19, a novel regulator of the mammalian cell cycle
08/03/2000WO2000045167A2 Non-invasive method for detecting target rna
08/03/2000WO2000044941A1 A method of treating anemia
08/03/2000WO2000044908A2 Comp/tsp-1, comp/tsp-2 and other tsp chimeric proteins
08/03/2000WO2000044906A2 GENES IDENTIFIED AS REQUIRED FOR PROLIFERATION IN $i(ESCHERICHIA COLI)
08/03/2000WO2000044903A1 Platelet-derived growth factor/vascular endothelial growth factor-like growth factor h, and uses thereof
08/03/2000WO2000044901A1 Transcriptional regulation of the human beta3-adrenergic receptor gene
08/03/2000WO2000044899A1 Her-2/neu fusion proteins
08/03/2000WO2000044897A1 Method of treating restenosis by antisense targeting of c-myc
08/03/2000WO2000044896A1 Internal ribosome entry site (ires), vector containing same and uses thereof
08/03/2000WO2000044895A1 Method and medicament for inhibiting the expression of a defined gene
08/03/2000WO2000044894A1 Method for isolating apoptosis-inducing dna sequences and detection system
08/03/2000WO2000044879A1 Aggressive prostate cancer sublines selected by androgen deprivation
08/03/2000WO2000044784A1 Nucleic acid and amino acid sequences
08/03/2000WO2000044782A2 Ewing's tumour antigen, nucleic acid and antibodies
08/03/2000WO2000044779A1 MurA
08/03/2000WO2000044774A2 Inhibition of stat3 signal transduction for human cancer therapy
08/03/2000WO2000044438A1 Delivery of macromolecules into cells
08/03/2000WO2000044410A2 Composition and method for obtaining specific immunisation against one or more antigens using different recombinant vectors
08/03/2000WO2000044409A1 Formulations comprising antisense nucleotides to connexins
08/03/2000WO2000044405A1 Dmsa promoters and derivatives thereof used for controlled expression of foreign genes
08/03/2000WO2000044401A1 Use of a melanoma inhibiting activity factor (mia) for cartilage and bone repair
08/03/2000WO2000044400A1 Treatment for diabetes
08/03/2000WO2000044391A2 Plasminogen kringle 4 region fragments and methods of use
08/03/2000WO2000044230A1 A method of controlling fungal pathogens, and agents useful for same
08/03/2000WO2000028061A3 Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
08/03/2000WO2000027874A3 Nucleic acids encoding transferrin receptor-like proteins and products related thereto
08/03/2000WO2000026254A3 Antibodies binding to the aav capsid, antibodies modifying cytotropism, method for targeted gene transfer
08/03/2000WO2000024896A3 Biological material for preparing pharmaceutical compositions for treating mammals
08/03/2000WO2000024415A3 Methods for regulating angiogenesis and vascular integrity using trk receptor ligands
08/03/2000WO2000024412A3 Use of vegf-c or vegf-d gene or protein to prevent restenosis
08/03/2000WO2000023587A3 Gene therapy of alzheimer's disease by delivery of an encoded apolipoprotein e
08/03/2000WO2000022137A3 Selectively replicating viral vectors
08/03/2000WO2000017346A3 Hairpin hybridizer molecules for modulation of gene expression
08/03/2000WO2000014240A3 Attenuated salmonella sp12 mutants as antigen carriers
08/03/2000WO2000009691A9 Bpc-1: a secreted brain specific protein expressed and secreted by prostate and bladder cancer cells
08/03/2000WO2000009675A9 Adenovirus formulations for gene therapy
08/03/2000WO2000009669A9 Human mesencephalon cell lines and methods of use therefor
08/03/2000WO2000006589A9 Prostate derived ets factor
08/03/2000WO2000004876A9 Controlled release of bioactive substances
08/03/2000WO1999062561A3 Gene therapy method
08/03/2000WO1999057132A8 Secreted proteins and polynucleotides encoding them
08/03/2000DE19903495A1 Ewing-Tumor-Antigen und Nukleinsäure Ewing's tumor antigen and nucleic acid
08/03/2000CA2730386A1 Formulations comprising antisense nucleotides to connexins
08/03/2000CA2361621A1 Inhibition of stat3 signal transduction for human cancer therapy
08/03/2000CA2361353A1 Product and method for obtaining specific immunisation with one or more antigens
1 ... 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 ... 870